GlaxoSmithKline: Human Genome Sciences Files BLA For Benlysta

10th Jun 2010 11:45

LONDON (Dow Jones)--GlaxoSmithKline PLC (GSK.LN), a global pharmaceutical and healthcare company, said Thursday that Human Genome Sciences Inc. (HGSI) has submitted a Biologics License Application to the U.S. Food and Drug Administration, for Benlysta for reducing disease activity in adult patients with autoantibody-positive systemic lupus erythematosus who are receiving standard therapy. MAIN FACTS: -Benlysta (Belimumab) is being developed by GSK and HGS under a co-development and commercialization agreement entered into in 2006. -Belimumab is not approved or licensed anywhere in the world. -Shares at 1040 GMT up 3.5 pence, or 0.3%, at 1166 pence. -By Tommy Stubbington, Dow Jones Newswires; 44-20-7842-9268; [email protected] (END) Dow Jones Newswires June 10, 2010 06:45 ET (10:45 GMT)